Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,466.46 +442.62 (+0.67%) CMC Crypto 200
1,438.25 +14.15 (+0.99%)
AXIM Biotechnologies, Inc. (AXIM)
| Previous close | 0.0127 |
| Open | 0.0115 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0090 - 0.0115 |
| 52-week range | 0.0090 - 0.0400 |
| Volume | |
| Avg. volume | 510,751 |
| Market cap | 3.035M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 22 May 2024 - 26 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit. Dur
- GlobeNewswire
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has received an additional order for its electronic readers designed to analyze both of the Company’s proprietary diagnostics assays f
- GlobeNewswire
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has signed an agreement with contract manufacturer Auer Precision for the production of its two FD
